Post-COVID-19 neurocandidiasis.
Miguel A MirandaSandra C SousaVera L MontesPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2021)
Associated with a significant morbidity and mortality, neurocandidiasis affects severely immunocompromised patients, especially if recently treated with antibiotics or corticosteroids. We present the case of a 70-year-old man admitted to an intensive care unit due to a Sars-Cov-2 pneumonia, with fever, coma, and multifocal neurological deficits reported 13 days after extubation. After isolation of Candida albicans in both urine and blood cultures and a brain MRI with multiple gadolinium-enhanced ring lesions, a diagnosis of neurocandidiasis was assumed and aggressive antifungal therapy started. During treatment, the patient developed a hospital-acquired pneumonia with fatal outcome.
Keyphrases
- candida albicans
- sars cov
- intensive care unit
- end stage renal disease
- newly diagnosed
- biofilm formation
- respiratory failure
- coronavirus disease
- ejection fraction
- healthcare
- respiratory syndrome coronavirus
- prognostic factors
- magnetic resonance imaging
- traumatic brain injury
- mechanical ventilation
- chronic kidney disease
- acute care
- peritoneal dialysis
- cerebral ischemia
- emergency department
- computed tomography
- acute kidney injury
- community acquired pneumonia
- multiple sclerosis
- case report
- contrast enhanced
- white matter
- bone marrow
- cardiac surgery
- stem cells
- pseudomonas aeruginosa